We performed a phase II study combining 41.8 degrees C whole body @entity221 with ICE chemotherapy, i.e. @entity1260 (5 g/m(2)), @entity3003 (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for @entity1 with @entity3620 . Of 27 chemon  ive, non-metastatic @entity1 enrolled, 25 @entity1 were evaluable for response. Overall response rate was 20% (five partial remissions; 95% CI 8.9-39.1%). Median survival time from the start of treatment for all @entity1 was 76.6 weeks (95% CI 65.4-87.8 weeks). Progression free survival for all @entity1 measured 29.6 weeks (95% CI 24.4-34.7 weeks). One year overall survival was 68% and 2 year overall survival was 20%. Major treatment toxicities included grade 3/4 @entity1398 and @entity882 in 74 and 33% of treatment cycles, respectively. One @entity1 died due to @entity295 . These promising results are consistent with continued clinical investigation; a phase III clinical trial with whole body @entity221 as the independent variable has been initiated.

XXXX , @entity3003 and etoposide combined with 41.8 degrees C whole body @entity221 for @entity3620 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity3620 :: ('MESH:C562839', 'Disease') :: ['malignant pleural mesothelioma'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide'] @entity221 :: ('MESH:D005334', 'Disease') :: ['hyperthermia']
@entity1260 :: (MESH:D007069,Chemical) :: ['Ifosfamide']
